DDI_Type	Interaction_Name
DDI Type 0	The risk or severity of bleeding can be increased when Drug 1 is combined with Drug 2.
DDI Type 1	The risk or severity of hemorrhage can be increased when Drug 1 is combined with Drug 2.
DDI Type 2	The therapeutic efficacy of Drug 1 can be decreased when used in combination with Drug 2.
DDI Type 3	The therapeutic efficacy of Drug 1 can be increased when used in combination with Drug 2.
DDI Type 4	The risk or severity of bleeding and bruising can be increased when Drug 1 is combined with Drug 2.
DDI Type 5	The risk or severity of gastrointestinal bleeding can be increased when Drug 1 is combined with Drug 2.
DDI Type 6	The risk or severity of bleeding and hemorrhage can be increased when Drug 1 is combined with Drug 2.
DDI Type 7	Drug 1 may increase the anticoagulant activities of Drug 2.
DDI Type 8	The risk or severity of QTc prolongation can be increased when Drug 1 is combined with Drug 2.
DDI Type 9	Drug 1 may decrease the excretion rate of Drug 2 which could result in a higher serum level.
DDI Type 10	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Drug 1 is combined with Drug 2.
DDI Type 11	The risk or severity of methemoglobinemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 12	Drug 1 may decrease effectiveness of Drug 2 as a diagnostic agent.
DDI Type 13	Drug 1 may increase the QTc-prolonging activities of Drug 2.
DDI Type 14	The risk or severity of adverse effects can be increased when Drug 1 is combined with Drug 2.
DDI Type 15	Drug 1 may increase the neuromuscular blocking activities of Drug 2.
DDI Type 16	The risk or severity of hypertension can be increased when Drug 1 is combined with Drug 2.
DDI Type 17	Drug 1 may decrease the antihypertensive activities of Drug 2.
DDI Type 18	The risk or severity of elevated intracranial pressure can be increased when Drug 1 is combined with Drug 2.
DDI Type 19	Drug 1 may increase the hypertensive activities of Drug 2.
DDI Type 20	The serum concentration of Drug 1 can be increased when it is combined with Drug 2.
DDI Type 21	The excretion of Drug 1 can be decreased when combined with Drug 2.
DDI Type 22	The serum concentration of Drug 1 can be decreased when it is combined with Drug 2.
DDI Type 23	The metabolism of Drug 1 can be increased when combined with Drug 2.
DDI Type 24	The metabolism of Drug 1 can be decreased when combined with Drug 2.
DDI Type 25	The risk or severity of nephrotoxicity can be increased when Drug 1 is combined with Drug 2.
DDI Type 26	The risk or severity of neuromuscular blockade can be increased when Drug 1 is combined with Drug 2.
DDI Type 27	Drug 1 may increase the neurotoxic activities of Drug 2.
DDI Type 28	Drug 1 may increase the nephrotoxic activities of Drug 2.
DDI Type 29	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 30	The risk or severity of renal failure can be increased when Drug 1 is combined with Drug 2.
DDI Type 31	The risk or severity of hyperkalemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 32	The excretion of Drug 1 can be increased when combined with Drug 2.
DDI Type 33	The risk or severity of seizure can be increased when Drug 1 is combined with Drug 2.
DDI Type 34	The bioavailability of Drug 1 can be decreased when combined with Drug 2.
DDI Type 35	The risk or severity of immunosuppression can be increased when Drug 1 is combined with Drug 2.
DDI Type 36	Drug 1 may increase the hepatotoxic activities of Drug 2.
DDI Type 37	Drug 1 may increase the immunosuppressive activities of Drug 2.
DDI Type 38	The risk or severity of neutropenia can be increased when Drug 1 is combined with Drug 2.
DDI Type 39	The risk or severity of myelosuppression can be increased when Drug 1 is combined with Drug 2.
DDI Type 40	Drug 1 may increase the excretion rate of Drug 2 which could result in a lower serum level and potentially a reduction in efficacy.
DDI Type 41	The risk or severity of Cardiovascular Impairment can be increased when Drug 1 is combined with Drug 2.
DDI Type 42	Drug 1 can cause an increase in the absorption of Drug 2 resulting in an increased serum concentration and potentially a worsening of adverse effects.
DDI Type 43	Drug 1 may increase the antiplatelet activities of Drug 2.
DDI Type 44	The risk or severity of hypokalemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 45	The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Drug 1 is combined with Drug 2.
DDI Type 46	Drug 1 may increase the photosensitizing activities of Drug 2.
DDI Type 47	The risk or severity of serotonin syndrome can be increased when Drug 1 is combined with Drug 2.
DDI Type 48	The risk or severity of CNS depression can be increased when Drug 1 is combined with Drug 2.
DDI Type 49	Drug 1 may increase the sedative activities of Drug 2.
DDI Type 50	Drug 1 may increase the serotonergic activities of Drug 2.
DDI Type 51	Drug 1 may increase the central nervous system depressant (CNS depressant) activities of Drug 2.
DDI Type 52	The risk or severity of serotonin syndrome and hypomania can be increased when Drug 1 is combined with Drug 2.
DDI Type 53	The risk or severity of sedation, somnolence, and CNS depression can be increased when Drug 1 is combined with Drug 2.
DDI Type 54	The risk or severity of sedation can be increased when Drug 1 is combined with Drug 2.
DDI Type 55	The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Drug 1 is combined with Drug 2.
DDI Type 56	The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Drug 1 is combined with Drug 2.
DDI Type 57	The risk or severity of renal failure and hypertension can be increased when Drug 1 is combined with Drug 2.
DDI Type 58	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Drug 1 is combined with Drug 2.
DDI Type 59	Drug 1 may increase the neuroexcitatory activities of Drug 2.
DDI Type 60	The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Drug 1 is combined with Drug 2.
DDI Type 61	The risk or severity of pseudotumor cerebri can be increased when Drug 1 is combined with Drug 2.
DDI Type 62	The absorption of Drug 1 can be decreased when combined with Drug 2.
DDI Type 63	The risk or severity of hypoglycemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 64	Drug 1 may increase the thrombogenic activities of Drug 2.
DDI Type 65	The risk or severity of myopathy can be increased when Drug 1 is combined with Drug 2.
DDI Type 66	The risk or severity of myopathy and rhabdomyolysis can be increased when Drug 1 is combined with Drug 2.
DDI Type 67	The risk or severity of hyponatremia can be increased when Drug 1 is combined with Drug 2.
DDI Type 68	Drug 1 may increase the fluid retaining and vasopressor activities of Drug 2.
DDI Type 69	The risk or severity of hypotension can be increased when Drug 1 is combined with Drug 2.
DDI Type 70	Drug 1 may increase the hypotensive activities of Drug 2.
DDI Type 71	The risk or severity of angioedema can be increased when Drug 1 is combined with Drug 2.
DDI Type 72	The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 73	The risk or severity of orthostatic hypotension and syncope can be increased when Drug 1 is combined with Drug 2.
DDI Type 74	The risk or severity of hypotension and orthostatic hypotension can be increased when Drug 1 is combined with Drug 2.
DDI Type 75	The risk or severity of orthostatic hypotension and dizziness can be increased when Drug 1 is combined with Drug 2.
DDI Type 76	The risk or severity of lactic acidosis can be increased when Drug 1 is combined with Drug 2.
DDI Type 77	The risk or severity of myelosuppression, anemia, and severe leukopenia can be increased when Drug 1 is combined with Drug 2.
DDI Type 78	Drug 1 may increase the hyperkalemic activities of Drug 2.
DDI Type 79	The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Drug 1 is combined with Drug 2.
DDI Type 80	The risk or severity of gastrointestinal irritation can be increased when Drug 1 is combined with Drug 2.
DDI Type 81	The risk or severity of hyperglycemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 82	The risk or severity of tendinopathy can be increased when Drug 1 is combined with Drug 2.
DDI Type 83	Drug 1 may increase the hypokalemic activities of Drug 2.
DDI Type 84	The risk or severity of electrolyte imbalance can be increased when Drug 1 is combined with Drug 2.
DDI Type 85	The risk or severity of fluid retention can be increased when Drug 1 is combined with Drug 2.
DDI Type 86	The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when Drug 1 is combined with Drug 2.
DDI Type 87	The risk or severity of ulceration can be increased when Drug 1 is combined with Drug 2.
DDI Type 88	The risk or severity of CNS depression and hypotonia can be increased when Drug 1 is combined with Drug 2.
DDI Type 89	The risk or severity of Tachycardia can be increased when Drug 1 is combined with Drug 2.
DDI Type 90	Drug 1 may decrease the sedative activities of Drug 2.
DDI Type 91	Drug 1 may increase the analgesic activities of Drug 2.
DDI Type 92	Drug 1 can cause a decrease in the absorption of Drug 2 resulting in a reduced serum concentration and potentially a decrease in efficacy.
DDI Type 93	The risk or severity of hypertension can be decreased when Drug 1 is combined with Drug 2.
DDI Type 94	The risk or severity of sedation and somnolence can be increased when Drug 1 is combined with Drug 2.
DDI Type 95	Drug 1 may increase the arrhythmogenic activities of Drug 2.
DDI Type 96	Drug 1 may increase the hypoglycemic activities of Drug 2.
DDI Type 97	Drug 1 may increase the bradycardic activities of Drug 2.
DDI Type 98	Drug 1 may increase the vasoconstricting activities of Drug 2.
DDI Type 99	Drug 1 may increase the orthostatic hypotensive activities of Drug 2.
DDI Type 100	The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when Drug 1 is combined with Drug 2.
DDI Type 101	Drug 1 may increase the bronchoconstrictory activities of Drug 2.
DDI Type 102	The risk or severity of cardiotoxicity can be increased when Drug 1 is combined with Drug 2.
DDI Type 103	The risk or severity of hypertension and tardive dyskinesia can be increased when Drug 1 is combined with Drug 2.
DDI Type 104	The risk or severity of hyperthermia and oligohydrosis can be increased when Drug 1 is combined with Drug 2.
DDI Type 105	The risk or severity of orthostatic hypotension can be increased when Drug 1 is combined with Drug 2.
DDI Type 106	Drug 1 may increase the anticholinergic activities of Drug 2.
DDI Type 107	The risk or severity of gastrointestinal ulceration can be increased when Drug 1 is combined with Drug 2.
DDI Type 108	The risk or severity of urinary retention can be increased when Drug 1 is combined with Drug 2.
DDI Type 109	The risk or severity of constipation can be increased when Drug 1 is combined with Drug 2.
DDI Type 110	The risk or severity of liver damage can be increased when Drug 1 is combined with Drug 2.
DDI Type 111	The risk or severity of thrombocytopenia can be increased when Drug 1 is combined with Drug 2.
DDI Type 112	The serum concentration of the active metabolites of Drug 1 can be increased when Drug 1 is used in combination with Drug 2.
DDI Type 113	The risk or severity of QTc prolongation and hypotension can be increased when Drug 1 is combined with Drug 2.
DDI Type 114	The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Drug 1 is combined with Drug 2.
DDI Type 115	The risk or severity of myopathy and weakness can be increased when Drug 1 is combined with Drug 2.
DDI Type 116	The risk or severity of bradycardia can be increased when Drug 1 is combined with Drug 2.
DDI Type 117	The risk or severity of Cardiac Arrhythmia can be increased when Drug 1 is combined with Drug 2.
DDI Type 118	Drug 1 may increase the antihypertensive activities of Drug 2.
DDI Type 119	The risk or severity of hypotension and syncope can be increased when Drug 1 is combined with Drug 2.
DDI Type 120	The risk or severity of hypotension and priapism can be increased when Drug 1 is combined with Drug 2.
DDI Type 121	Drug 1 may increase the antipsychotic activities of Drug 2.
DDI Type 122	The risk or severity of bleeding and thrombocytopenia can be increased when Drug 1 is combined with Drug 2.
DDI Type 123	The risk or severity of Tachycardia and drowsiness can be increased when Drug 1 is combined with Drug 2.
DDI Type 124	The risk or severity of urinary retention and constipation can be increased when Drug 1 is combined with Drug 2.
DDI Type 125	The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Drug 1 is combined with Drug 2.
DDI Type 126	Drug 1 may increase the smooth muscle relaxing activities of Drug 2.
DDI Type 127	Drug 1 may increase the hypertensive and vasoconstricting activities of Drug 2.
DDI Type 128	Drug 1 may increase the sympathomimetic activities of Drug 2.
DDI Type 129	Drug 1 may decrease the neuromuscular blocking activities of Drug 2.
DDI Type 130	The risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Drug 1 is combined with Drug 2.
DDI Type 131	The risk or severity of hypocalcemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 132	The risk or severity of ototoxicity and nephrotoxicity can be increased when Drug 1 is combined with Drug 2.
DDI Type 133	The risk or severity of dehydration can be increased when Drug 1 is combined with Drug 2.
DDI Type 134	Drug 1 may increase the vasodilatory activities of Drug 2.
DDI Type 135	The risk or severity of vasospastic reactions can be increased when Drug 1 is combined with Drug 2.
DDI Type 136	The risk or severity of reduced gastrointestinal motility can be increased when Drug 1 is combined with Drug 2.
DDI Type 137	The protein binding of Drug 1 can be decreased when combined with Drug 2.
DDI Type 138	Drug 1 may increase the cardiodepressant activities of Drug 2.
DDI Type 139	The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Drug 1 is combined with Drug 2.
DDI Type 140	The risk or severity of bleeding and gastrointestinal bleeding can be increased when Drug 1 is combined with Drug 2.
DDI Type 141	The risk or severity of congestive heart failure, bleeding, hypotension, and Tachycardia can be increased when Drug 1 is combined with Drug 2.
DDI Type 142	Drug 1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Drug 2.
DDI Type 143	Drug 1 may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Drug 2.
DDI Type 144	The bioavailability of Drug 1 can be increased when combined with Drug 2.
DDI Type 145	The risk or severity of adverse effects can be decreased when Drug 1 is combined with Drug 2.
DDI Type 146	Drug 1 may decrease the hypoglycemic activities of Drug 2.
DDI Type 147	The serum concentration of aripiprazole, an active metabolite of Drug 1, can be decreased when used in combination with Drug 2.
DDI Type 148	Drug 1 may decrease the anticoagulant activities of Drug 2.
DDI Type 149	The risk or severity of liver enzyme elevations can be increased when Drug 1 is combined with Drug 2.
DDI Type 150	Drug 1 may increase the arrhythmogenic and cardiotoxic activities of Drug 2.
DDI Type 151	Drug 1 may decrease the nephrotoxic activities of Drug 2.
DDI Type 152	The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Drug 1 is combined with Drug 2.
DDI Type 153	Drug 1 may increase the tachycardic activities of Drug 2.
DDI Type 154	The risk or severity of myocardial depression can be increased when Drug 1 is combined with Drug 2.
DDI Type 155	The risk or severity of bronchospasm, shortness of breath, and dyspnea can be increased when Drug 1 is combined with Drug 2.
DDI Type 156	The risk or severity of granulocytopenia can be increased when Drug 1 is combined with Drug 2.
DDI Type 157	The risk or severity of hypercalcemia can be increased when Drug 1 is combined with Drug 2.
DDI Type 158	Drug 1 may increase the Pseudotumor Cerebri activities of Drug 2.
DDI Type 159	The serum concentration of the active metabolites of Drug 1 can be reduced when Drug 1 is used in combination with Drug 2 resulting in a loss in efficacy.
DDI Type 160	The risk or severity of hyponatremia and water intoxication can be increased when Drug 1 is combined with Drug 2.
DDI Type 161	Drug 1 may increase the vasopressor activities of Drug 2.
DDI Type 162	Drug 1 may increase the hypolipidaemic activities of Drug 2.
DDI Type 163	Drug 1 may increase the atrioventricular blocking (AV block) activities of Drug 2.
DDI Type 164	The risk or severity of respiratory depression can be increased when Drug 1 is combined with Drug 2.
DDI Type 165	The risk or severity of QTc prolongation can be decreased when Drug 1 is combined with Drug 2.
DDI Type 166	Drug 1 may decrease the fluid retaining and vasopressor activities of Drug 2.
DDI Type 167	Drug 1 may decrease the hypertensive activities of Drug 2.
DDI Type 168	Drug 1 may decrease the stimulatory activities of Drug 2.
DDI Type 169	The risk or severity of hypotension and CNS depression can be increased when Drug 1 is combined with Drug 2.
DDI Type 170	Drug 1 may decrease the bronchodilatory activities of Drug 2.
DDI Type 171	The risk or severity of cardiovascular complications can be increased when Drug 1 is combined with Drug 2.
DDI Type 172	Drug 1 may increase the bradycardic, atrioventricular blocking (AV block), and arrhythmogenic activities of Drug 2.
DDI Type 173	Drug 1 may decrease the cardiotoxic activities of Drug 2.
DDI Type 174	The risk of a hypersensitivity reaction to Drug 1 is increased when it is combined with Drug 2.
DDI Type 175	Drug 1 may increase the uterotonic activities of Drug 2.
DDI Type 176	The risk or severity of neutropenia and thrombocytopenia can be increased when Drug 1 is combined with Drug 2.
DDI Type 177	Drug 1 may increase the hypotensive and Electrolyte Disturbance activities of Drug 2.
DDI Type 178	The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Drug 1 is combined with Drug 2.
DDI Type 179	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Drug 1 is combined with Drug 2.
DDI Type 180	Drug 1 may increase effectiveness of Drug 2 as a diagnostic agent.
DDI Type 181	Drug 1 may increase the myopathic rhabdomyolysis activities of Drug 2.
DDI Type 182	Drug 1 may increase the opioid antagonism activities of Drug 2.
DDI Type 183	Drug 1 may increase the Change in thyroid function activities of Drug 2.
DDI Type 184	The risk or severity of QTc prolongation and torsade de pointes can be increased when Drug 1 is combined with Drug 2.
DDI Type 185	The risk or severity of serotonin syndrome and seizure can be increased when Drug 1 is combined with Drug 2.
DDI Type 186	The risk or severity of extrapyramidal symptoms can be increased when Drug 1 is combined with Drug 2.
DDI Type 187	The risk or severity of serotonin syndrome and opioid toxicity can be increased when Drug 1 is combined with Drug 2.
DDI Type 188	Drug 1 may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Drug 2.
DDI Type 189	Drug 1 may increase the alpha-adrenergic activities of Drug 2.
DDI Type 190	Drug 1 may decrease the hypotensive activities of Drug 2.
DDI Type 191	The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Drug 1 is combined with Drug 2.
DDI Type 192	The risk or severity of hypertension and cardiovascular complications can be increased when Drug 1 is combined with Drug 2.
DDI Type 193	The risk or severity of edema formation can be increased when Drug 1 is combined with Drug 2.
DDI Type 194	The risk or severity of peripheral neuropathy can be increased when Drug 1 is combined with Drug 2.
DDI Type 195	The risk or severity of sedation and CNS depression can be increased when Drug 1 is combined with Drug 2.
DDI Type 196	Drug 1 may increase the diuretic activities of Drug 2.
DDI Type 197	The risk or severity of renal failure and hypotension can be increased when Drug 1 is combined with Drug 2.
DDI Type 198	Drug 1 may increase the ototoxic activities of Drug 2.
DDI Type 199	The risk or severity of osteomalacia can be increased when Drug 1 is combined with Drug 2.
DDI Type 200	The risk or severity of serotonin syndrome can be decreased when Drug 1 is combined with Drug 2.
DDI Type 201	The serum concentration of SN-38, an active metabolite of Drug 1, can be increased when used in combination with Drug 2.
DDI Type 202	The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Drug 1 is combined with Drug 2.
DDI Type 203	The risk or severity of metabolic acidosis can be increased when Drug 1 is combined with Drug 2.
DDI Type 204	Drug 1 may increase the hypotensive and vasodilatory activities of Drug 2.
DDI Type 205	The risk or severity of cytopenia can be increased when Drug 1 is combined with Drug 2.
DDI Type 206	Drug 1 may increase the atrioventricular blocking (AV block) and arrhythmogenic activities of Drug 2.
DDI Type 207	Drug 1 may decrease the antiplatelet activities of Drug 2.
DDI Type 208	The risk or severity of congestive heart failure and hypotension can be increased when Drug 1 is combined with Drug 2.
DDI Type 209	The risk or severity of electrolyte abnormality can be increased when Drug 1 is combined with Drug 2.
DDI Type 210	The risk or severity of rhabdomyolysis can be increased when Drug 1 is combined with Drug 2.
DDI Type 211	The risk or severity of hypertension and Tachycardia can be increased when Drug 1 is combined with Drug 2.
DDI Type 212	The risk or severity of sedation and orthostatic hypotension can be increased when Drug 1 is combined with Drug 2.
DDI Type 213	The risk or severity of rhabdomyolysis, myoglobinuria, and elevated creatine kinase (CPK) can be increased when Drug 1 is combined with Drug 2.
DDI Type 214	The serum concentration of desmethylclomipramine, an active metabolite of Drug 1, can be increased when used in combination with Drug 2.
DDI Type 215	The serum concentration of dextroamphetamine, an active metabolite of Drug 1, can be increased when used in combination with Drug 2.
DDI Type 216	Drug 1 may increase the hypercalcemic activities of Drug 2.
DDI Type 217	The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Drug 1 is combined with Drug 2.
DDI Type 218	The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Drug 1 is combined with Drug 2.
DDI Type 219	The risk or severity of myopathy and rhabdomyolysis can be decreased when Drug 1 is combined with Drug 2.
DDI Type 220	The risk or severity of hypersensitivity reaction can be increased when Drug 1 is combined with Drug 2.
